The global computational biology market was valued at USD 2.65 Billion in 2020 and is projected to grow at a CAGR of 20.8% during the forecast period. Factors driving the growth of the computational biology market include increase in R&D for drug discovery, practice in population centered sequencing assignments and surge in bioinformatics research.
Computational biology is concerned with the use of computers for biological problems, most prominently problems in evolutionary and molecular biology. This area is also referred to as bioinformatics and these two terms are often used interchangeably. The usage of computational biology has escalated for gene sequencing and expansion, protein transcription, structural and functional epigenomic, genomics and metagenomics for the analysis of protein-protein interactions, and 3-D protein structure analysis.
Regionally, North America accounted for the largest market share of the global computational biology market attributable to industry-academia collaborations. Leading players of the global computational biology market include Computing Group Inc., Simulation Plus Inc., Compugen Ltd., Genedata AG, Insilico Biotechnology AG, Certara, Accelrys, Entelos, Rhenovia Pharma SAS, Nimbus Discovery LLC among others.
Computational Biology Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 11.92 Billion|
|Growth Rate||CAGR of 20.8% during 2021-2028|
|Segment Covered||Application,Services, End-use, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, Middle East & Africa|
|Key Players Profiled||Computing Group Inc., Simulation Plus Inc., Compugen Ltd., Genedata AG, Insilico Biotechnology AG, Certara, Accelrys, Entelos, Rhenovia Pharma SAS, Nimbus Discovery LLC among others.|
Key segments of the global computational biology market
Application Overview, 2018-2028 (USD Billion)
- Cellular & Biological Simulation
- Drug Discovery & Disease Modelling
- Preclinical Drug Development
- Clinical Trials
- Human Body Simulation Software
Services Overview, 2018-2028 (USD Billion)
End-use Overview, 2018-2028 (USD Billion)
Regional Overview, 2018-2028 (USD Billion)
- North America
- United Kingdom
- Asia Pacific
- Latin America
- Middle East & Africa
- South Africa
Reasons for the study
- Increase in bioinformatics research
- Increasing number of clinical studies in pharmacogenomics and pharmacokinetics
- Growth of drug designing and disease modeling
What does the report include?
- The study on the global computational biology market includes qualitative factors such as drivers, restraints and opportunities
- The study covers qualitative and quantitative analysis of the market segmented on the basis of application, service and end-use. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global computational biology market is suitable for all the players across the value chain including product manufacturing companies, suppliers/distributors, R&D labs, CROs, healthcare organizations, medical reimbursement and insurance providers
- Venture capitalists and investors looking for more information on the future outlook of the global computational biology market
- Consultants, analysts, researchers, and academicians looking for insights shaping the global computational biology market
The term ‘computational biologist’ can encompass several roles, including data analyst, data curator, database developer, statistician, mathematical modeler, bioinformatician, software developer, ontologist and many more. Computers are now essential components of modern biological research, and scientists are being asked to adopt new skills in computational biology and master new terminology. Key to good computational biology is the selection and use of appropriate software. Software tools are often implementations of a particular algorithm that may be well-suited for particular types of data; for example, in de novo assembly, an Overlap-Layout-Consensus assembler is optimized for longer sequence reads, whereas de Bruijn graphs were designed with short reads in mind. Choosing software employing the most appropriate algorithm saves a lot of time.
Based on the application drug discovery is anticipated to be the fastest growing segment over the forecast period, as it helps enabling personalized medicine, predict drug effects in patients, the finding of new uses for existing drugs and improvement of the success rate of new drugs in the clinic. Based on the services that global computational biology industry is bifurcated into in-house and contract. Compared to the in-house services, contract services offers higher cost-effectiveness, just-in-time delivery with a single point of contact and offers access to wide range of industry software led to its higher adoption. On the basis of end-user, the global computational biology market is segmented into industry, commercial and academics. The segment with highest global computational biology market share is accredited to commercial. It is ascribed to growth of drug designing, personalized medicine and disease modelling, increasing number of clinical studies in pharmacokinetics and pharmacogenomics, and increase in bioinformatics research.
North America accounted for the largest share of the global computational biology market in 2020. Moreover, Asia is likely to show lucrative growth during the forecast period. North America leads the global computational biology market share with increasing initiatives and investments for R&D of novel drugs, drug discovery, technological advancements and disease modelling in biological computations. In addition to that, the US government channeled billions for the progress of synthetic biology and computational biology. The global computational biology market of Canada is anticipated to have significant growth over the forecast period, primarily due the Canadian government developing interest to advance the computational biology.